Skip to main content
. 2022 Sep 20;2022:6302234. doi: 10.1155/2022/6302234

Figure 1.

Figure 1

The high expression of PLK4 in ccRCC. (a) The expression of PLK4 in different human tumors from The Cancer Genome Atlas (TCGA) database was analyzed by the Tumor Immunity Estimation Resource (TIMER). PLK4 was upregulated in (b) analysis of PLK4 gene expression levels between ccRCC and its paraneoplastic tissues using the UALCAN database. (c) Differential expression of PLK4 in normal and cancerous tissues by the GEO database. (d) The differential expression of PLK4 in tumor tissues and their paired paracancerous tissues was obtained by paired sample analysis of TCGA. (e) The expression of PLK4 at different clinical stages in ccRCC. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.